Skip to content

Study of Treatment's Echocardiographic Mechanisms

Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis: Study of Treatment's Echocardiographic Mechanisms (CLOVERS-STEM)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03913403
Enrollment
210
Registered
2019-04-12
Start date
2019-04-30
Completion date
2021-05-01
Last updated
2021-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Keywords

Fluid Management, Sepsis-Induced Hypotension, Vasopressors, Cardiac Contractility

Brief summary

This ancillary study determines whether the Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS) \[ClinicalTrials.gov Identifier: NCT03434028\] treatment arms (restrictive fluids strategy vs. liberal fluid strategy) for early sepsis-induced hypotension are associated with differences in cardiac structure and function based on an echocardiogram at 24 hours after randomization. Secondarily, this ancillary study explores possible heterogeneity of treatment effect based on an echocardiogram performed shortly after randomization in CLOVERS.

Detailed description

The Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis: Study of Treatment's Echocardiographic Mechanisms (CLOVERS-STEM) study is an ancillary study to CLOVERS, a parent multi-center, prospective, phase 3 randomized non-blinded interventional trial of fluid treatment strategies in the first 24 hours for patients with sepsis-induced hypotension. The CLOVERS trial attempts to determine the impact of a restrictive fluids strategy (vasopressors first followed by rescue fluids) as compared to a liberal fluid strategy (fluids first followed by rescue vasopressors) on 90-day in-hospital mortality in patients with sepsis-induced hypotension. This ancillary study obtains echocardiograms among CLOVERS-enrolled patients who consent to CLOVERS-STEM at baseline and 24 hours later (secondarily, this study also measures serum troponin levels at baseline and 24 hours) to pursue three aims: 1. Evaluate for differences in left ventricular global longitudinal strain at 24 hours after randomization between treatment arms; 2. Evaluate for differences in right ventricular end diastolic area to left ventricular end diastolic area ratio at 24 hours after randomization between treatment arms; 3. Explore possible heterogeneity of treatment effect based on baseline echocardiogram.

Interventions

PROCEDUREECHO

Echocardiogram at baseline and 24 hours later

PROCEDUREBlood Draw

Blood Draw for Troponin Levels - 5ml at baseline and 24 hours later

Sponsors

Beth Israel Deaconess Medical Center
CollaboratorOTHER
Montefiore Medical Center
CollaboratorOTHER
Oregon Health and Science University
CollaboratorOTHER
Vanderbilt University Medical Center
CollaboratorOTHER
Wake Forest University Health Sciences
CollaboratorOTHER
Harborview Injury Prevention and Research Center
CollaboratorOTHER
Intermountain Health Care, Inc.
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Enrolled in the Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS) Trial

Exclusion criteria

* Lack of Informed Consent for this Ancillary Study * Allergy to Ultrasound-Enhancing Agents

Design outcomes

Primary

MeasureTime frameDescription
Left Ventricular Contractility at 24 hours24 +/- 6 HoursLeft Ventricular Global Longitudinal Strain
Right Ventricular Structure at 24 hours24 +/- 6 hoursRight Ventricular End Diastolic Area to Left Ventricular End Diastolic Area Ratio
Day 3 delta SOFAat 72 hoursDifference between baseline and day 3 Sequential Organ Failure Assessment (SOFA) scores

Secondary

MeasureTime frameDescription
Right Ventricular Contractility at 24 hours24 +/- 6 hoursRight Ventricular Longitudinal Strain

Countries

United States

Contacts

Primary ContactValerie Aston
valerie.aston@imail.org801-507-4607
Backup ContactCarlos Barbagelata, MS
carlos.barbagelata@imail.org801-507-4607

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026